Skip to content

The Prognostic Value of Serum Biomarkers in Ewing's Sarcoma

The Prognostic Value of Serum Biomarkers in Ewing's Sarcoma

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05100368
Enrollment
1000
Registered
2021-10-29
Start date
2021-04-02
Completion date
2021-07-01
Last updated
2023-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma, Ewing

Keywords

sarcoma; ewing

Brief summary

Extraction of laboratory data from blood tests prior to surgical and chemotherapy and other histological, clinical and instrumental data related to the patient's history from the digitized medical Digitized medical records and analysis of the same. The medical records of 1000 patients from January 1, 2000, until December 31, 2020

Interventions

OTHERpatients

Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis

Sponsors

Istituto Ortopedico Rizzoli
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis; * Patients with age ≥ 2 years; * Minimum follow-up duration of 2 years; * Medical records, complete blood work and instrumental examinations; Regular follow-up.

Exclusion criteria

* Patients with Ewing's sarcoma or osteosarcoma who have received medical treatment (surgery radiotherapy or chemotherapy) in other institutions prior to admission to the Rizzoli Orthopaedic Institute.

Design outcomes

Primary

MeasureTime frameDescription
5-year survivalat baseline (Day0)Evaluation of 5-year survival in relation to histologic, laboratory, clinical, and instrumental laboratory, clinical and instrumental factors

Secondary

MeasureTime frameDescription
Rate of local recurrenceat baseline (Day0)Evaluation of the rate of local recurrence and distant metastasis in relation to prognostic factors histological, laboratory, clinical and instrumental factors;

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026